Leukemia

The Venclexta-based regimen improved complete response rates in patients with acute myeloid leukemia and myelodysplastic syndromes.

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia.

Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in patients with chronic myeloid leukemia.

Tecartus demonstrated similar effectiveness across age groups of patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.

Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed or refractory B-ALL.

Pediatric patients with standard-risk B-ALL demonstrated significantly improved disease-free survival with Blincyto plus chemotherapy versus chemotherapy alone.

The FDA approved several drugs throughout November for the treatment of diseases including leukemia and biliary tract cancer, in addition to a diagnostic for solid cancers.

The FDA has approved updated drug labeling for Sandoz in the treatment of B-cell chronic lymphocytic leukemia.

New treatments for acute lymphoblastic leukemia may lead to fewer side effects than chemotherapy, as they target cancer cells more precisely, an expert said.

Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.

Danziten, a new formulation of nilotinib, may improve treatment adherence in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based on findings from the FELIX trial.

During October, the FDA approved drugs to treat diseases including breast cancer, lung cancer, leukemia and gastric cancer.

Treatment with Scemblix was shown to improve response rates in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.

Jylamvo is an oral liquid formulation of methotrexate originally approved in 2022 for adults with acute lymphoblastic leukemia, among other diseases.

From “The Office” star opening up in a new interview to Charley Steiner revealing his multiple myeloma journey, here is this week’s cancer news.

Patients with relapsed or refractory CLL or SLL may benefit from receiving Brukinsa instead of Imbruvica, as Brukinsa demonstrated superior effectiveness.

More than 60% of patients with relapsed or refractory KMT2Ar acute leukemia responded to the menin inhibitor revumenib.

I’ve recently started on chemotherapy pills instead of infusions and the bitterness reminds me to accept not only the bitterness of the pill, but in life too.

As a survivor of acute myeloid leukemia, some things are no longer going to be normal, but who wants to be normal?

From good news for a rock star to the deaths of stage and screen stars, here’s what’s happening in the cancer space this week.

CAR-T cell therapies administered in an outpatient setting may be safe and feasible without intensive remote monitoring in hematologic malignancies.

Before receiving treatment for acute myeloid leukemia, I made it a point to take advantage of all the resources that were available to me.

While spending weeks in the hospital for acute myeloid leukemia, I tried eight fun things to keep me busy.